CB-03-01 - TheKaneShop

Có thể bạn quan tâm

Skip to content Sale! Add to Wishlist

Home / Powder for Hairloss Treatment Research CB-03-01

$100.00 – $500.00

CAS 19608-29-8

Purity >98%

Research use only

Quantity

Choose an option1 gram5 gram10 gramClear

CB-03-01 quantity Add to cart SKU: N/A Category: Powder for Hairloss Treatment Research

Description
Additional information
Reviews (0)

Description

Cortexolone 17 alpha-propionate (CB-03-01) is a new topical and peripherally selective androgen receptor antagonist.[1]

Targets

Androgen receptor

In vitro

The aim of one in vitro study was to investigate the antiandrogenic activity of a new monoester of cortexolone, cortexolone 17alpha-propionate (CB-03-01). Although the compound displayed a strong local antiandrogenic activity in hamster’s flank organ test. Its pharmacological activity seemed to be primarily related to its ability to antagonistically compete at androgen receptor level; nevertheless its primary pharmacological target needs to be further investigated. The topical activity of cortexolone 17alpha-propionate with the apparent absence of systemic effects makes this compound to have the potential of representing a novel and safe therapeutic approach for androgen-dependent skin disorders.[1]

In vivo

Cortexolone 17alpha-propionate displayed a strong local antiandrogenic activity in hamster’s flank organ test, however, it did not exhibit antiandrogenic activity in rats, nor did it affect gonadotropins hypersecretion. As topical antiandrogen, the steroid resulted about 4 times more active than progesterone and, when compared to known antiandrogen standards, it was about 3 times more potent than flutamide, about 2 times more effective than finasteride and approximately as active as cyproterone acetate. Weight Bench or Station – Buy / Sell from% s sustaviron 250 healthrider hrel11900 home weight system manuals, user guides and other materials. Its pharmacological activity seemed to be primarily related to its ability to antagonistically compete at androgen receptor level; nevertheless its primary pharmacological target needs to be further investigated.[1]